Bristol-Myers Squibb Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Bristol-Myers Squibb has been growing earnings at an average annual rate of 2.8%, while the Pharmaceuticals industry saw earnings growing at 6.2% annually. Revenues have been growing at an average rate of 8.3% per year.

Belangrijke informatie

2.8%

Groei van de winst

-0.4%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	12.4%
Inkomstengroei	8.3%
Rendement op eigen vermogen	-42.1%
Nettomarge	-15.3%
Volgende winstupdate	06 Feb 2025

Recente prestatie-updates uit het verleden

Recent updates

Opbrengsten en kosten

Hoe Bristol-Myers Squibb geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

BASE:BMY Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	47,435	-7,258	8,077	9,470
30 Jun 24	46,509	-6,541	7,891	9,200
31 Mar 24	45,534	-6,148	7,884	9,252
31 Dec 23	45,006	8,025	7,678	9,112
30 Sep 23	44,935	8,285	7,874	9,146
30 Jun 23	45,187	7,963	7,784	9,321
31 Mar 23	45,848	7,311	7,636	9,274
31 Dec 22	46,159	6,327	7,703	9,201
30 Sep 22	46,738	6,677	7,785	9,209
30 Jun 22	47,144	6,617	7,724	9,319
31 Mar 22	46,960	6,251	7,808	9,266
31 Dec 21	46,385	6,994	7,655	10,195
30 Sep 21	45,468	-5,405	7,747	9,371
30 Jun 21	44,384	-5,079	7,712	9,279
31 Mar 21	42,810	-6,219	7,442	9,182
31 Dec 20	42,518	-9,015	7,618	10,048
30 Sep 20	39,395	-44	6,626	8,655
30 Jun 20	34,862	-563	5,921	7,737
31 Mar 20	31,006	954	5,399	6,868
31 Dec 19	26,145	3,439	4,969	6,066
30 Sep 19	24,173	5,655	4,549	5,281
30 Jun 19	23,857	6,203	4,568	5,185
31 Mar 19	23,288	5,144	4,585	5,245
31 Dec 18	22,561	4,920	4,523	6,253
30 Sep 18	22,037	1,432	4,230	5,184
30 Jun 18	21,600	376	4,327	5,109
31 Mar 18	21,040	919	4,438	4,958
31 Dec 17	20,776	1,007	4,749	6,085
30 Sep 17	20,570	4,229	4,896	4,697
30 Jun 17	20,238	4,586	4,877	4,589
31 Mar 17	19,965	4,836	4,929	4,513
31 Dec 16	19,427	4,457	4,815	4,477
30 Sep 16	18,471	3,366	4,947	4,366
30 Jun 16	17,618	2,870	4,977	4,310
31 Mar 16	16,910	1,574	4,871	4,181
31 Dec 15	16,560	1,565	4,831	4,037
30 Sep 15	16,531	1,775	4,697	4,001
30 Jun 15	16,383	1,790	4,625	3,896
31 Mar 15	16,109	2,253	4,628	3,869
31 Dec 14	15,879	2,004	4,717	3,913
30 Sep 14	16,062	2,717	4,666	3,715
30 Jun 14	16,206	2,688	4,734	3,690
31 Mar 14	16,365	2,891	4,858	3,683
31 Dec 13	16,385	2,563	4,923	3,715

Kwaliteitswinsten: BMY is currently unprofitable.

Groeiende winstmarge: BMY is currently unprofitable.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: BMY is unprofitable, but has reduced losses over the past 5 years at a rate of 2.8% per year.

Versnelling van de groei: Unable to compare BMY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: BMY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.3%).

Rendement op eigen vermogen

Hoge ROE: BMY has a negative Return on Equity (-42.13%), as it is currently unprofitable.

Bristol-Myers Squibb Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Bristol-Myers Squibb Company to Report Q3, 2024 Results on Oct 31, 2024

Bristol-Myers Squibb Company Announces Intangible Asset Impairment Charges for the Three Months Ended June 30, 2024

Bristol-Myers Squibb Company to Report Q2, 2024 Results on Jul 26, 2024

Bristol-Myers Squibb Company to Report Q1, 2024 Results on Apr 25, 2024

Bristol-Myers Squibb Company to Report Q4, 2023 Results on Feb 02, 2024

Recent updates

Bristol Myers Squibb Presents New Long-Term Data from the EMERGENT Program Evaluating Covenfy in Adults with Schizophrenia At Psych Congress 2024

Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data At Psych Congress 2024

U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)

Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (Deucravacitinib) Efficacy in Both Moderate-To-Severe Scalp Psoriasis and in A Real-World Setting

U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY (xanomeline and Trospium Chlorx), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

Bristol Myers Squibb Announces New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis

Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from Checkmate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® Plus Yervoy® in Advanced Melanoma

Bristol-Myers Squibb Company to Report Q3, 2024 Results on Oct 31, 2024

Bristol Myers Squibb Announces Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS (Mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma

European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Bristol-Myers Squibb Company Announces Intangible Asset Impairment Charges for the Three Months Ended June 30, 2024

Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

Bristol-Myers Squibb Company to Report Q2, 2024 Results on Jul 26, 2024

Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024

Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024

Bristol Myers Squibb Announces Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial

Bristol Myers Squibb’S Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented At 2024 Asco® Annual Meeting

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine

Bristol Myers Squibb Announces New Four-Year Results from the POETYK PSO Long-Term Extension Trial of Sotyktu (Deucravacitinib) Treatment in Adult Patients with Moderate-To-Severe Plaque Psoriasis

Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approves by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma

Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Bristol Myers Squibb Announces KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

European Commission Expands Approval of Bristol Myers Squibb’S Reblozyl® (Luspatercept)

Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (Oozanimod) in Patients with Moderate to Severe Active Crohn's Disease

Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024

Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

Bristol-Myers Squibb Company, Annual General Meeting, May 07, 2024

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Karuna Therapeutics, Inc. (NasdaqGM:KRTX) from Capital International Investors, FMR LLC, The Vanguard Group, Inc., T. Rowe Price Group, Inc. (NasdaqGS:TROW) and others.

FDA Advisory Committee Votes in Favor of Bristol-Myers Squibb Company and 2seventy bio, Inc. Abecma for Triple-Class Exposed Multiple Myeloma in Further Lines of Therapy

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Bristol-Myers Squibb Company to Report Q1, 2024 Results on Apr 25, 2024

U.S. Food and Drug Administration Approves Bristol-Myers Squibb Company's Opdivo

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of RayzeBio, Inc. (NasdaqGM:RYZB).

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of RayzeBio, Inc. (NasdaqGM:RYZB).

Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)

Bristol-Myers Squibb Company Announces Management Changes

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer

Bristol Myers Squibb and 2seventy bio, Inc. Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study

Bristol-Myers Squibb Company Announces Three Regulatory Acceptances from the U.S. Food and Drug Administration (FDA) and Japan’S Ministry of Health, Labour and Welfare (MHLW) for Breyanzi

Bristol Myers Squibb Announces the First Disclosure of Data from the Phase 3 CheckMate -67T Trial

Bristol-Myers Squibb Company Receives Positive Chmp Opinion for Car T Cell Therapy Abecma (Idecabtagene Vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib)

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Bristol Myers Squibb Announces Results from the Phase 3 Randomized Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab)

Bristol Myers Squibb Data At Asco Gu 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers

European Medicines Agency Validates Bristol Bristol-Myers Squibb Company Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic Ros1-Positive Non-Small Cell Lung Cancer and Ntrk-Positive Solid Tumors

Bristol-Myers Squibb Company (NYSE:BMY) entered into definitive merger agreement to acquire RayzeBio, Inc. (NasdaqGM:RYZB) for $3.8 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.6 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.5 billion.

Bristol-Myers Squibb Company to Report Q4, 2023 Results on Feb 02, 2024

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden